Inato
Inato is a Paris-based AI-powered clinical trial platform connecting 25+ pharmaceutical sponsors with 6,000+ research sites across 50+ countries, offering AI site selection and AI patient pre-screening to accelerate enrollment and improve trial diversity.
- Company typePrivate
- Founded2016
- HeadquartersParis, France
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Inato does
Inato SAS is a Paris-based clinical trial technology company founded in 2016 that operates a two-sided marketplace connecting pharmaceutical sponsors with clinical research sites. The platform serves 25+ enterprise pharmaceutical companies (including Sanofi, Pfizer, Amgen, Lilly, AstraZeneca, and Kailera) and 6,000+ research sites across more than 50 countries, with the core value proposition centered on accelerating trial enrollment and improving patient diversity through better site selection and patient matching. The platform is organized into three integrated capabilities: early trial planning, AI Site Selection (drawing on verified data from 5,500+ sites, launched September 2025), and AI Patient Pre-Screening (launched January 2025). Underlying the AI features is a proprietary multimodal LLM pipeline that uses visual language models and reasoning models to interpret patient records without OCR, validated through a peer-reviewed paper in Nature Digital Medicine.
The technology stack integrates with the broader clinical trial ecosystem through partnerships with RealTime eClinical Solutions (combining TrialAlign site data, September 2025), CRIO (Partners Program, April 2025), and eClinPro (Site CTMS integration, April 2026). Documented integrations also include ClinicalTrials.gov and EHR systems. The business model is a quote-based enterprise B2B subscription, with direct field sales to pharmaceutical sponsors complemented by a self-serve marketplace for research sites. The company is ISO 27001 and HIPAA compliant and has raised approximately $35.5 million in total disclosed funding across seed (2017), Series A (2020, $14M led by Cathay Innovation and Obvious Ventures), and Series A2 (March 2023, $20M led by Cathay Innovation). The company has 51-100 employees and is led by Co-founder and CEO Kourosh Davarpanah alongside Co-founder and CSO Liz Beatty and Co-founder Philippe Ravaud.
Inato firmographics
Firmographics- Name
- Inato
- Legal name
- Inato SAS
- Website
- https://inato.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Inato is a Paris-based AI-powered clinical trial platform connecting 25+ pharmaceutical sponsors with 6,000+ research sites across 50+ countries, offering AI site selection and AI patient pre-screening to accelerate enrollment and improve trial diversity.
- Ownership category
- akta.pro rank
Inato industry classification
Industry- Product category
- Clinical Trial Technology
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Site & Investigator Platforms (Site Payments, Feasibility, Activation) (HLACAOAJ)
- akta.pro secondary industry
- Clinical Trial Site Operations & Study Coordination (HLAGACAE)
Keywords
Where Inato is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Inato business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Platform Subscription / Marketplace Access: Inato operates a marketplace model where pharmaceutical sponsors pay for access to site data, site selection tools, and patient pre-screening capabilities. Research sites access the platform to find trial opportunities and use pre-screening tools. The platform serves as a two-sided marketplace connecting sponsors and sites.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise B2B platform - custom pricing |
Go-to-market motion1 record
Distribution channels5 records
Marketing channels6 records
Inato product offering
Product offeringCore offering
Inato provides an AI-powered two-sided marketplace platform that connects pharmaceutical sponsors with clinical research sites. Its offering combines early trial planning, AI-driven site selection using verified data from 5,500+ sites, and AI patient pre-screening that automates chart review against protocol eligibility criteria, reducing manual review time by up to 90%. The platform serves 25+ enterprise pharma sponsors and 6,000+ research sites across 50+ countries.
Product overview
Inato is a unified AI-powered clinical trial platform that combines early planning, AI site selection, and AI patient pre-screening into one integrated system. The core Inato Platform connects 25 sponsors with 6,000+ research sites across 50+ countries. The platform consists of the Inato Marketplace (for site-investigator matching), AI Site Selection (leveraging verified data from 5,500+ sites for data-driven decisions), and AI Patient Pre-Screening (automating chart review with up to 90% time savings). Multiple case studies document outcomes including 181% enrollment achievement in asthma trials, 66% faster oncology enrollment, and significant time/cost savings through AI-powered workflows.
Differentiator
Problem solved
Functional benefit
Products and services
- Inato Platform AI-powered unified platform that connects pharmaceutical sponsors with clinical research sites for trial planning, site selection, and patient enrollment. Combines the Inato Marketplace, AI Site Selection, and AI Patient Pre-Screening into one integrated system for 25+ sponsors and 6,000+ research sites across 50+ countries.
- AI Site Selection AI-powered site selection capability enabling pharmaceutical sponsors to identify and match qualified, motivated research sites based on actual capabilities and patient access, using verified data from 5,500+ research sites.
- AI Patient Pre-Screening AI-powered patient pre-screening tool that automates chart review and pre-screening by evaluating patient records against protocol inclusion/exclusion criteria, providing rationale and source citations. Reduces chart review times by up to 90% with 95% accuracy.
- Inato Marketplace Two-sided data marketplace connecting pharmaceutical sponsors with clinical research sites, matching relevant investigators and sites for trials based on site capabilities and patient access data. Research sites can self-register to access trial opportunities; sponsors gain access to a database of 6,000+ research sites across 50+ countries.
Quantifiable outcome
- Up to 90% reduction in chart review times using AI patient pre-screening
- +8 more outcomes
Companies that use Inato
Customer profileNamed customers8 records
Segments3 records
Ideal customer profiles3 records
Inato technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability8 records
Feature4 records
Inato partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- RealTime eClinical SolutionscoreStrategic partnership announced September 23, 2025 to enhance site selection and trial enrollment. Combines RealTime-Devana's TrialAlign site data with Inato's patient access data, providing sponsors and CROs with unparalleled site performance insights. The partnership expands Inato's network by bringing 50+ large networks (2,000+ sites) onto the platform. Sites gain preferred access to Inato's AI patient pre-screening solution.
- CRIOcoreInato joined CRIO's Partners Program, connecting CRIO-affiliated research sites with Inato's platform for trial discovery, site recommendations, and AI-powered patient pre-screening. Listed in CRIO's Partners Directory under Business Development and Feasibility category.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Inato competitors and assessment
Company assessmentDirect peers
- Deep 6 AI: AI-native clinical trial patient matching and site selection platform serving pharma sponsors. Closely comparable to Inato's AI Site Selection and AI Patient Pre-Screening products, with similar use of EHR-derived data for eligibility assessment.
- Mendel: AI platform that structures clinical and biomedical text to accelerate clinical trial recruitment. Competes with Inato on AI-driven patient cohort identification and chart review automation.
- Trial Library: Patient recruitment and clinical trial matching platform using AI and EHR data. Directly comparable to Inato on site and patient matching for pharma-sponsored trials.
Emerging players
- BEK Health: AI-powered clinical trial pre-screening platform focused on automating patient identification from EHR data. Competes with Inato's AI Patient Pre-Screening product with a narrower site-supply focus.
- Castor: Clinical trial platform providing EDC, eConsent, and decentralized trial capabilities for sponsors and sites. Overlaps with Inato on site-side trial enablement and patient data capture.
Broad incumbents
- IQVIA: Largest global CRO with extensive site network, real-world data assets, and AI-driven trial design and site selection offerings. Competes with Inato across the pharma sponsor workflow with broader service breadth.
- Labcorp Drug Development (Fortrea): Major global CRO (spun out from Labcorp) offering site selection, patient recruitment, and central lab services. Competes with Inato on sponsor-facing trial services with deeper enterprise relationships.
- Parexel: Global CRO providing site identification, patient recruitment, and clinical operations. Competes with Inato as a full-service sponsor partner with established biopharma relationships.
- Medidata (Dassault Systèmes): Leading clinical trial technology platform offering EDC, eCOA, randomization, and increasingly AI-driven trial operations. Overlaps with Inato on sponsor-side clinical operations and patient data workflows.
- Veeva Systems: Enterprise cloud software provider for life sciences, including Veeva Vault Clinical Suite used by sponsors and CROs. Competes with Inato on sponsor-facing trial planning and operations technology.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Inato social profiles
Digital presenceInato compliance and trust
Trust signalCompliance2 records
Inato financial estimates
Financial estimateRevenue estimate
Valuation estimate
Inato leadership team
Management profileNumber of profiles
Profiles5 records
Inato funding detail
Funding detailFunding overview
Funding rounds3 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Inato M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Inato
What does Inato do?
Inato provides an AI-powered two-sided marketplace platform that connects pharmaceutical sponsors with clinical research sites. Its offering combines early trial planning, AI-driven site selection using verified data from 5,500+ sites, and AI patient pre-screening that automates chart review against protocol eligibility criteria, reducing manual review time by up to 90%. The platform serves 25+ enterprise pharma sponsors and 6,000+ research sites across 50+ countries.
Is Inato a public or private company?
Inato is a private company. It is classified as venture growth investor backed and is currently operating.
When was Inato founded?
Inato was founded in 2016. It employs 51 to 100 people.
Where is Inato based?
Inato is headquartered in Paris, France, in the Europe region.
How does Inato make money?
One revenue line is on record: platform Subscription / Marketplace Access.
Who are Inato's main competitors?
Direct peers on record are Deep 6 AI, Mendel and Trial Library. Emerging players are BEK Health and Castor. Broad incumbents are IQVIA, Labcorp Drug Development (Fortrea), Parexel, Medidata (Dassault Systèmes) and Veeva Systems.
Does Inato have an API?
No public API is recorded for Inato.
What industry is Inato in?
Inato's product category is Clinical Trial Technology. Its primary akta.pro industry code is HLACAOAJ, Site & Investigator Platforms (Site Payments, Feasibility, Activation), with a secondary code of HLAGACAE, Clinical Trial Site Operations & Study Coordination. Its NAICS code is 5417 and its SIC code is 8731.